Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03752398 · ClinicalTrials.gov registry record · Phase 1
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 198
- Enrollment target
NCT03752398: Completed Phase 1 study, sponsored by Xencor.
NCT03752398 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 198 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (230% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03752398, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 198 participants
- Enrollment target
Study Summary
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.
Primary Outcome
Safety and tolerability
Interventions
- BIOLOGICAL XmAb®23104
- BIOLOGICAL Yervoy® (ipilimumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 1 |
What the finished NCT03752398 record still lists
NCT03752398 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (230% higher).
The record links to 0 conditions, and to 2 interventions - of which XmAb®23104 is the first listed.
NCT03752398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03752398 about?
NCT03752398 is a clinical study titled "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)". This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in sub...
What is the current status of trial NCT03752398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 198 participants. The study started on 2019-05-01. Estimated completion is 2024-02-15.
What interventions are being tested in trial NCT03752398?
The interventions under investigation include: XmAb®23104 (BIOLOGICAL), Yervoy® (ipilimumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03752398?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03752398's enrollment target sits among peer trials
198 277th of 2000 higher than 1,723 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI